A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome

PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Charles F. P., Feldman, Neil, Zheng, Yanping, Steininger, Teresa L., Grzeschik, Susanna M., Lai, Chinglin, Inhaber, Neil
Formato: Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098358/
https://www.ncbi.nlm.nih.gov/pubmed/20082240
http://dx.doi.org/10.1007/s11325-009-0320-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098358/
https://www.ncbi.nlm.nih.gov/pubmed/20082240
http://dx.doi.org/10.1007/s11325-009-0320-0

Ejemplares similares